Loomis Sayles & Co. L P Decreases Position in InMode Ltd. (NASDAQ:INMD)

Loomis Sayles & Co. L P trimmed its position in InMode Ltd. (NASDAQ:INMD) by 7.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 282,064 shares of the healthcare company’s stock after selling 23,502 shares during the period. Loomis Sayles & Co. L P owned 0.34% of InMode worth $4,781,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in INMD. Renaissance Technologies LLC lifted its stake in InMode by 11.6% in the 2nd quarter. Renaissance Technologies LLC now owns 2,068,396 shares of the healthcare company’s stock valued at $37,728,000 after buying an additional 214,200 shares in the last quarter. Doma Perpetual Capital Management LLC lifted its position in shares of InMode by 210.7% during the 2nd quarter. Doma Perpetual Capital Management LLC now owns 2,011,240 shares of the healthcare company’s stock worth $36,685,000 after purchasing an additional 1,363,841 shares during the last quarter. DDD Partners LLC lifted its position in shares of InMode by 19.4% during the 2nd quarter. DDD Partners LLC now owns 1,266,678 shares of the healthcare company’s stock worth $23,104,000 after purchasing an additional 205,947 shares during the last quarter. Federated Hermes Inc. lifted its position in InMode by 191.9% in the second quarter. Federated Hermes Inc. now owns 1,125,017 shares of the healthcare company’s stock valued at $20,520,000 after acquiring an additional 739,629 shares during the last quarter. Finally, Acadian Asset Management LLC lifted its position in InMode by 63.6% in the second quarter. Acadian Asset Management LLC now owns 1,124,887 shares of the healthcare company’s stock valued at $20,502,000 after acquiring an additional 437,122 shares during the last quarter. 68.04% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

INMD has been the topic of a number of recent research reports. BTIG Research initiated coverage on shares of InMode in a research note on Thursday, October 17th. They issued a “buy” rating and a $25.00 price objective on the stock. Needham & Company LLC restated a “hold” rating on shares of InMode in a research report on Thursday, October 31st. Finally, Barclays lowered their target price on shares of InMode from $29.00 to $27.00 and set an “overweight” rating on the stock in a research report on Monday, October 14th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $22.60.

InMode Price Performance

NASDAQ INMD opened at $19.49 on Thursday. The company’s fifty day moving average price is $17.53 and its two-hundred day moving average price is $17.49. InMode Ltd. has a 12 month low of $14.87 and a 12 month high of $26.80. The company has a market capitalization of $1.64 billion, a price-to-earnings ratio of 10.54 and a beta of 2.15.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.